Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Pharma Mar (PHMMF : OTC)

• Company Description    Pharma Mar SA is a biopharmaceutical company. It engaged in the discovery and development of marine-derived anticancer drugs. The company's product pipeline consists of PM1183, plitidepsin, and PM184 which are in clinical trial stage. It operates primarily in Germany, Italy, France, Switzerland, United Kingdom, Belgium and the United States. Pharma Mar SA is headquartered in Madrid, Spain. Number of Employees: 500

• Price / Volume Information    Yesterday's Closing Price: $99.90 Daily Weekly Monthly 20 Day Moving Average: 24 shares Shares Outstanding: (millions) Market Capitalization: $ (millions) Beta: 0.24 52 Week High: $105.60 52 Week Low: $52.54 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 3.32% 1.45% 12 Week -4.40% -13.20% Year To Date 23.23% 10.02%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL Avda. De los Reyes 1 Pol. Ind. La Mina - Madrid,U3 28770 ESP ph: 34-91-846-6000 fax: 34-91-846-6001 investorrelations@pharmamar.com http://www.pharmamar.com

• General Corporate Information    Officers JOSE M- FERNANDEZ SOUSA-FARO - Chairman PEDRO FERNANDEZ PUENTES - Vice-Chairman MONTSERRAT ANDRADE DETRELL - Director EDUARDO SERRA REXACH - Director CARLOS SOLCHAGA CATALAN - Director Peer Information Pharma Mar (CORR.) Pharma Mar (RSPI) Pharma Mar (CGXP) Pharma Mar (BGEN) Pharma Mar (GTBP) Pharma Mar (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: E8075H159 SIC: 8880 Fiscal Year Fiscal Year End: December Last Reported Quarter: - Next Expected EPS Date: - Share - Related Items Shares Outstanding: Most Recent Split Date: 7.00 (0.08:1) Beta: 0.24 Market Capitalization: $ (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 06/25/2025 - $0.00 Next EPS Report Date: -

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 8.59 Price/Cash Flow: 241.19 Price / Sales: - EPS Growth vs. Year Ago Period: -% vs. Previous Quarter: -% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/25 - - 03/31/25 - - 12/31/24 - - ROA 06/30/25 - - 03/31/25 - - 12/31/24 - - Current Ratio 06/30/25 - - 03/31/25 - 2.97 12/31/24 - 3.03 Quick Ratio 06/30/25 - - 03/31/25 - 2.33 12/31/24 - 2.40 Operating Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Net Margin 06/30/25 - - 03/31/25 - - 12/31/24 - - Pre-Tax Margin 06/30/25 - - 03/31/25 - - 12/31/24 - 6.85 Book Value 06/30/25 - - 03/31/25 - - 12/31/24 - - Inventory Turnover 06/30/25 - - 03/31/25 - - 12/31/24 - 0.17 Debt-to-Equity 06/30/25 - - 03/31/25 - 0.20 12/31/24 - 0.19 Debt-to-Capital 06/30/25 - - 03/31/25 - 16.35 12/31/24 - 16.06

Powered by Zacks Investment Research ©